Literature DB >> 28988786

Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients.

Zahava Vadasz1, Yuval Tal2, Menachem Rotem3, Vered Shichter-Confino4, Keren Mahlab-Guri5, Yael Graif6, Aharon Kessel7, Nancy Agmon-Levin8, Ramit Maoz-Segal8, Shmuel Kivity9, Shira Benor9, Idit Lachover-Roth10, Yuri Zeldin11, Migel Stein12, Ori Toker2, Gamal Hassoun13, Shira Bezalel-Rosenberg5, Elias Toubi7, Ilan Asher5, Zev Sthoeger5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28988786     DOI： 10.1016/j.jaip.2017.08.035

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  9 in total

1.  Combination therapy with omalizumab and an immune-suppressive agent for resistant chronic spontaneous rrticaria - A real-life experience.

Authors:  Ramit Maoz-Segal; Tanya Levy; Soad Haj-Yahia; Irena Offengenden; Mona Iancovich-Kidon; Nancy Agmon-Levin
Journal:  World Allergy Organ J       Date:  2020-08-04       Impact factor: 4.084

Review 2.  Chronic Spontaneous Urticaria: The Devil's Itch.

Authors:  Sarbjit S Saini; Allen P Kaplan
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jul - Aug

Review 3.  Update on Omalizumab for Urticaria: What's New in the Literature from Mechanisms to Clinic.

Authors:  Désirée E S Larenas-Linnemann; Claudio A S Parisi; Carla Ritchie; Ricardo Cardona-Villa; Ivan Cherrez-Ojeda; Annia Cherrez; Luis Felipe Ensina; Elizabeth Garcia; Iris V Medina; Mónica Rodríguez-González; Jorge Mario Sánchez Caraballo
Journal:  Curr Allergy Asthma Rep       Date:  2018-05-09       Impact factor: 4.806

Review 4.  Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress.

Authors:  Ana M Giménez-Arnau; Andaç Salman
Journal:  Drugs       Date:  2020-11       Impact factor: 9.546

5.  A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.

Authors:  H Lapeere; M Baeck; A Stockman; V Sabato; M Grosber; M Moutschen; J Lambert; L Vandebuerie; L de Montjoye; H Rabijns; K Allewaert; R Schrijvers
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-08-19       Impact factor: 6.166

6.  Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.

Authors:  Yudi Chen; Miao Yu; Xiaojie Huang; Ping Tu; Peikun Shi; Marcus Maurer; Zuotao Zhao
Journal:  World Allergy Organ J       Date:  2021-01-05       Impact factor: 4.084

Review 7.  Expert consensus on the use of omalizumab in chronic urticaria in China.

Authors:  Zuotao Zhao; Tao Cai; Hong Chen; Liuqing Chen; Yudi Chen; Xiang Gao; Xinghua Gao; Songmei Geng; Yinshi Guo; Fei Hao; Guodong Hao; Yan Hu; Hongzhong Jin; Zhehu Jin; Chengxin Li; Haili Li; Jie Li; Yanming Li; Yunsheng Liang; Guanghui Liu; Qiang Liu; Hai Long; Lin Ma; Yuanyuan Shang; Yuxin Song; Zhiqiang Song; Xiangyang Su; Haijing Sui; Qing Sun; Yuemei Sun; Jianping Tang; Xunliang Tong; Huiying Wang; Gang Wang; Lianglu Wang; Siqin Wang; Li Xiang; Ting Xiao; Zhiqiang Xie; Leping Ye; Yongmei Yu; Chunlei Zhang; Litao Zhang; Shuchen Zhang; Rui Zheng; Lili Zhi; Wei Zhou; Ying Zou; Marcus Maurer
Journal:  World Allergy Organ J       Date:  2021-12-05       Impact factor: 4.084

Review 8.  Pediatric usage of Omalizumab: A promising one.

Authors:  Lin Yu; Huishan Zhang; Jianwei Pan; Leping Ye
Journal:  World Allergy Organ J       Date:  2021-12-11       Impact factor: 4.084

Review 9.  Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.

Authors:  Martin Metz; Zahava Vadasz; Emek Kocatürk; Ana M Giménez-Arnau
Journal:  Clin Rev Allergy Immunol       Date:  2020-08       Impact factor: 8.667
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.